Filing Flows › 8-K events › Quoin Pharmaceuticals
Quoin Pharmaceuticals: entry into a material definitive agreement
Form 8-K filed Nov 4, 2026 · items 1.01
What the filing says
On November 4, 2026, Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may sell, from time to time, American Depositary Shares (“ADSs”), each representing 35 of the Company’s ordinary
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.